Compare SSYS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSYS | ARVN |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.1M | 658.2M |
| IPO Year | 2012 | 2018 |
| Metric | SSYS | ARVN |
|---|---|---|
| Price | $9.89 | $7.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | $12.33 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 1.2M | 816.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $3.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.34 | $6.06 |
| 52 Week High | $12.78 | $14.22 |
| Indicator | SSYS | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 23.63 |
| Support Level | $7.80 | $7.35 |
| Resistance Level | $9.92 | $8.22 |
| Average True Range (ATR) | 0.50 | 0.43 |
| MACD | 0.16 | -0.09 |
| Stochastic Oscillator | 67.54 | 0.85 |
Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.